Head-to-head · Cost-Efficiency Index
Nex Gen Health Rx vs Solaya MD
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Nex Gen Health Rx
Shoppers who want a named pharmacy and an itemized checkout, and who will read the homepage figure as the annual prepay it is.
Visit Nex Gen Health RxSolaya MD
Readers who want the pharmacy and the prescribing group identifiable before signing up, and who do not mind creating an account to learn the price.
Visit Solaya MDThe verdict
Nex Gen Health Rx and Solaya MD tie on the Cost-Efficiency Index at 62/100, so neither wins outright on the numbers. For most shoppers we'd start with Nex Gen Health Rx (ranked #208, a hair above #210) — Shoppers who want a named pharmacy and an itemized checkout, and who will read the homepage figure as the annual prepay it is. But Solaya MD is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Nex Gen Health Rx.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Nex Gen Health Rx | Solaya MD |
|---|---|---|
| Cost-Efficiency Index | 62/100 | 62/100 |
| Semaglutide / mo | $190 per 30-day supply month-to-month (the homepage's $99 is the 360-day prepay rate) | Not disclosed — the only public figure is an unscoped "Pricing starts at $185" with no molecule and no billing cycle |
| Tirzepatide / mo | $239 per 30-day supply month-to-month (the homepage's $149 is the 360-day prepay rate) | Not disclosed — the same unscoped $185 floor is the only figure published for either molecule |
| Semaglutide / yr (modeled) | $2,280 | — |
| Tirzepatide / yr (modeled) | $2,868 | — |
| Coverage | Coverage not published | All 50 states |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #208 | #210 |
Nex Gen Health Rx
62/100Where the value is
- Names its pharmacy, Manifest Pharmacy, with a street address, and states the 503A class on the product pages
- The checkout itemizes what the price already covers, showing doctor support and monitoring at $99 and overnight shipping at $40 both marked free
- Full 30-, 90-, 180- and 360-day ladders for both molecules are reachable by a control on the product page, and the total was confirmed at checkout
The tradeoffs
- The homepage prints "for as low as $99.00 a month" and "$149.00 a month" with no basis stated; the basis appears only on a separate landing page, and it is a twelve-month plan paid in full
- That landing page sells $99 as "every month", "fixed price" and "price never increases" while its own fine print makes it conditional on $1,188 paid upfront
Solaya MD
62/100Where the value is
- Names its partner pharmacy, VialsRX, with a street address, phone number and website, revealed by a control on the FAQ
- Names the medical group and a medical director with an NPI number, which can be looked up independently
- Offers both oral and injectable routes and a low-dose program under one program price
The tradeoffs
- No drug-scoped price is published: the only public figure is "Pricing starts at $185" with no molecule, no dose and no billing cycle, and everything specific sits behind a create-account gate
- That figure sits above a line reading "clinician calls and care coaching available*" whose asterisk has no footnote anywhere on the page
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.